All In Biotech

Drug Trial Radar · NCT07775391

Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI

Phase Ⅰ/Ⅱa Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Intravenous Injection of Human Umbilical Cord Mesenchymal Stem Cells (hUC-MSCs) in Patients With Premature Ovarian Insufficiency (POI)

Last checked: Nov 19, 2026Latest source record: Aug 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

59

Planned (sponsor's estimate)

Start

Aug 3, 2026

Primary completion

Sep 30, 2028

Study completion Aug 2, 2029

Sponsor

Sponsor type
Industry
First posted
Aug 20, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI). The primary objective of the Phase I dose-escalation stage is to assess the safety and tolerability of intravenous infusion of hUC-MSCs injection for the treatment of POI, and to determine the recommended phase II dose (RP2D) for the Phase IIa clinical trial. The primary objective of the Phase IIa dose-expansion stage is to evaluate the efficacy of intravenous infusion of hUC-MSCs injection in POI treatment, and to generate data to support pivotal/confirmatory clinical trials.

Conditions

  • Premature Ovarian Insufficiency

Interventions

  • hUC-MSCs Injection (Phase I)Drug

    hUC-MSCs Injection, administered via intravenous infusion as a single dose on D0.

  • hUC-MSCs Injection (Phase IIa)Drug

    hUC-MSCs Injection, 3 infusions in total, dosing interval ≥7 days.

  • PlaceboDrug

    3 infusions in total, dosing interval ≥7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I : Incidence and number of subjects with treatment-emergent adverse events and serious adverse events.Time frame: 48 weeks
  2. Phase II :FSHTime frame: at Week 24 post-treatment
  3. Phase II :E2Time frame: at Week 24 post-treatment
  4. Phase II :AMHTime frame: at Week 24 post-treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.